Mats Sanden, MD, MBA

Cell Phone: 302-***-**** adpdns@r.postjobfree.com, www.linkedin.com/in/mats-sanden

Summary

Experienced and highly qualified Medical Director/Chief Medical Officer with Medical Affairs experience and extensive experience in Cutting Edge Precision/Personalized Medicine including Molecular Oncology Diagnostics, Molecular Pathology Diagnostics, microRNA technology, Molecular Infectious Disease Diagnostics, Pharmacogenomics, Molecular Genetics and Toxicology. Extensive Cross-Functional Team experience providing Medical Expertise to R&D, Marketing and Sales as well as to Clients.

Participated together with R&D, outside collaborators and KOLs in multiple clinical trials with results published in peer reviewed journals. Board Certified, and with expertise in both Anatomic and Clinical Pathology. Diverse medical experience including academic appointments, corporate medical positions, community healthcare, research, and start-up company. Fellowship in Dermatopathology MBA from George Washington University, Washington DC. CAP inspection team leader.

NYS Certification of Qualification in Clinical Chemistry, Histopathology, Oncology-Molecular and Cellular Tumor Markers and Clinical Toxicology.

Medical Licenses in PA, MD, NJ, NY, FL, TX as well as in several European countries.

Cross-cultural competence derived from international medical experience as well as working in a multinational company.

Skill Highlights

Medical Affairs Experience Board Certified in Anatomic and Clinical Pathology

Participating in phase III – IV clinical studies Molecular Oncology Diagnostics

Pharmacogenomics Molecular Pathology

Cross-Functional Team Leadership Experience Fellowship in Dermatopathology

microRNA technology CAP Inspector experience

Molecular Microbiology Toxicology

Molecular Infectious Disease Diagnostics Leadership/Communication skills

Research, Interpretation, and Analysis of Data Cross-cultural competence

Professional Experience

Chief Medical Officer and Laboratory Director (Remote Part time), Bensalem PA. Parkway Clinical Laboratory (PCL). 10/2007-Present

PCL is a CLIA-certified, CAP accredited national clinical reference laboratory performing routine and esoteric diagnostic testing utilizing Enzyme Immuno-Assay and LC-MS/MS technology Oversee/Supervise all functions of the laboratory operations. Review and approve SOPs, QA as well as QC data, CAPA and Proficiency test results. Supervise and ensure that the laboratory is in compliance with Federal and State regulations. Led the laboratory through multiple successful accreditation inspections including the initial inspections from CAP and NYS.

Mats Sanden Page 2

Medical and Laboratory Director (Remote Part time), Hamilton, NJ Medical Diagnostic Laboratory. LLC. (MDL). 12/2016-Present

MDL is a CLIA certified, CAP accredited national and international molecular infectious disease, women’s health and molecular genetics reference laboratory, specializing in high complexity, state-of-the-art, automated DNA-based molecular analyses by PCR and NGS technology providing services to physicians, laboratories and hospitals worldwide Oversee/Supervise all functions of the laboratory operations. Review and approve SOPs, QA as well as QC data, CAPA and Proficiency test result Supervise and ensure that the laboratory is in compliance with Federal and State regulations

Member Board of Directors Vanguard Laboratories Investment Group. Orange County, CA. 04/21-Present

Investment group dedicated to becoming a major force in providing clinical laboratory services in the state of California, United States.

Pathologist Locum Tenens Assignments,

Bassett Memorial Hospital, Cooperstown, NY, 09/09/2019-10/02/2019 Butler Memorial Hospital Butler, PA, 11/13/2019-01/29/2020 and 11/30/2020-02/19/2021 Samaritan Hospital Watertown, NY, 02/03/2020-02/28/2020 Providence Hospital Memorial and Sierra Campuses El Paso TX 07/07/21- 10/08/21

Medical Director & Laboratory Director, Philadelphia, PA. Rosetta Genomics Inc. (RGL) 05/2011- 03/2017

RGL was a CLIA certified, CAP accredited national and international molecular cancer diagnostic reference laboratory. RG had multiple, commercially available, cancer diagnostic tests based on molecular analysis by PCR and Assay technology providing services to physicians, laboratories, and hospitals worldwide. Led a biotech laboratory specializes in cutting edge molecular pathology utilized for oncology diagnostics. Directed the laboratory through several successful accreditation inspections by CAP and NYS Developed and led a new customer service department. Led and implemented a project that reduced TAT by 40%. Participated in clinical studies (phase III and IV) and published multiple articles with outside collaborators and R&D dept. Increased revenue by working closely with Marketing and Sales Directors to develop new marketing and educational material, including brochures, PPT presentations, letters to physicians and sales material. Maintained close contact with existing and new clients (oncologists, pathologists, and endocrinologists) resulting in increased revenue, increased client base and extensive collection of clinical data for future development and articles. Represented the company at national and international conferences. Participated in the startup process of a patient registry and was managing the registry. Oversaw projects for optimizing laboratory resources and increase efficiency. Set up a NGS mutation panel and provided Medical Consultations to Rosetta’s partner laboratory Admera Health, which performed tumor mutation and pharmacogenomics tests for our patients. Led the laboratory through launching of multiple new diagnostic tests, all achieving NYS approval. The company went into bankruptcy in early 2018.

Mats Sanden Page 3

Consulting Pathologist (Part time) Vineland and Woodbury, NJ Inspira Health Network, 07/2010- 11/2018

Providing consultations to the hospital systems laboratories.

Consulting Pathologist (Part time), Wrightstown, NJ Pathology Corporation of America 12/2009 – 06/2013

Provided dermatopathology consultations for a private pathology laboratory.

Consulting Pathologist (Part time), Lakewood and Union NJ. Lakewood Pathology Laboratory dba Plus Diagnostics, 01/2001 – 08/2012

Provided dermatopathology consultations for a private pathology laboratory.

Staff Pathologist Vineland, NJ. South Jersey Health Care, 07/2000- 06/2010

Collaborated with two colleagues in managing several hospital-based laboratories with annual volume of 12,000 surgical pathology cases, 20,000 cytology and 1.6 million clinical tests.

Assistant Professor of Pathology, Stratford NJ University of Medicine & Dentistry of New Jersey, 07/1998- 06/2000

Participated in managing a hospital-based pathology laboratory, as well as in teaching of esidents, medical, Dental and Nursing students.

Fellowship in Dermatopathology. Philadelphia, PA. Thomas Jefferson University, 07/1997-06/1998

Locum Tenant Family Practice Oppdal Norway Oppdal Legesenter 04/1997- 06/1998

Residency in Anatomic and Clinical Pathology, Washington DC Washington Hospital Center (Affiliated with George Washington University) 04/1993-03/1997

Locum Tenant Family Practice Verdal and Oppdal Norway Verdal and Oppdal Legesenter 07/1992- 03/1993

Internship Molndal Sweden Molndal University Hospital Gothenburg University 10/1990-07/1992 Including 6 months Surgery, 6 months Internal Medicine, 6 months Primary Care and 3 months Psychiatry

Instructor Department of Pathology. Gothenburg University, Gothenburg. Sweden Sahlgrenska University Hospital 06/1988-09/1990

Mats Sanden Page 4

Education

MBA George Washington University, Washington DC 08/2011 - 08/2013

MD Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 01/1983 - 06/1988

Certifications

Diplomat American Board of Pathology in Anatomic and Clinical Pathology Certification of Qualification from New York State in Oncology-molecular and cellular tumor markers Certification of Qualification from New York State in Histopathology Certification of Qualification from New York State in Clinical Chemistry Certification of Qualification from New York State in Clinical Toxicology.

Licenses

Pennsylvania New York New Jersey (Physician + New Jersey Bio-Analytical Laboratory Director License) Maryland Florida Texas Sweden Norway

Professional Membership

Fellow College of American Pathologists (CAP) Member Association for Molecular Pathology (AMP) Member United States and Canadian Academy of Pathology (USCAP) Member American College of Corporate Directors (ACCD)

Publications and Presentations:

Multicentre validation of a microRNA-based assay for diagnosing indeterminate thyroid nodules utilizing fine needle aspirate smears Gila Lithwick-Yanai, Nir Dromi, Alexander Shtabsky, Sara Morgenstern, Yulia Strenov, Meora Feinmesser Vladimir Kravtsov, Marino E Leon, Marián Hajdúch, Syed Z Ali, Christopher J VandenBussche, Xinmin Zhang, Leonor Leider-Trejo, Asia Zubkov, Sergey Vorobyov, Michal Kushnir, Yaron Goren, Sarit Tabak, Etti Kadosh, Hila Benjamin, Temima Schnitzer-Perlman, Hagai Marmor, Maria Motin, Danit Lebanony, Sharon Kredo-Russo, Heather Mitchell, Melissa Noller, Alexis Smith, Olivia Dattner, Karin Ashkenazi, Mats Sanden, Kenneth A Berlin, Dganit Bar, Eti Meiri J Clin Pathol doi:10.1136/jclinpath-201*-******. 10/26/2016

Clinicians’ Real World Perception of Pre-Nephrectomy Diagnostic Biopsy Performance as a Driver of Reduction in Unnecessary Surgeries in Renal Tumors Kristin Fahy, Lauren Augustine, Mats O Sanden, E. Robert Wassman. Journal of Kidney Cancer and VHL 2015; 2(1):1-14

Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary. Pentheroudakis G, Pavlidis N, Fountzilas G, Krikelis D, Goussia A, Stoyianni A, Sanden M, St Cyr B, Yerushalmi N, Benjamin H, Meiri E, Chajut A, Rosenwald S, Aharonov R, Spector Y. Mol Cancer. 2013 Jun 10; 12(1):57. Epub ahead of print

Mats Sanden Page 5

Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinoma. Yael Spector, Eddie Fridman, Shai Rosenwald, Sofia Zilber,Yajue Huang, Iris Barshack, Orit Zion, Heather Mitchell, Mats Sanden, Eti Meiri. Mol Oncol. 2013 Jun; 7(3):732-8. doi: 10.1016/j.molonc.2013.03.002. Epub 2013 Mar 26.

Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors. Pentheroudakis G, Spector Y, Krikelis D, Kotoula V, Meiri E, Malamou-Mitsi V, Fountzilas G, Sanden M, Pavlidis N, Benjamin H, Aharonov R. Clin Exp Metastasis. 2012 Nov 4. Epub ahead of print

Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. Gilad S, Lithwick-Yanai G, Barshack I, Benjamin S, Krivitsky I, Edmonston TB, Bibbo M, Thurm C, Horowitz L, Huang Y, Feinmesser M, Hou JS, St Cyr B, Burnstein I, Gibori H, Dromi N, Sanden M, Kushnir M, Aharonov R. J Mol Diagn. 2012 Sep; 14(5):510-7. doi: 10.1016/j.jmoldx.2012.03.004. Epub 2012 Jun 27.

A second-generation microRNA-based assay for diagnosing tumor tissue origin. Meiri E, Mueller WC, Rosenwald S, Zepeniuk M, Klinke E, Edmonston TB, Werner M, Lass U, Barshack I, Feinmesser M, Huszar M, Fogt F, Ashkenazi K, Sanden M, Goren E, Dromi N, Zion O, Burnstein I, Chajut A, Spector Y, Aharonov R. Oncologist. 2012; 17(6):801-12. Epub 2012 May 22.

Observational study of real world clinical performance of microRNA molecular profiling for cancer of unknown primary (CUP). Mats Olof Sanden, Robert Wassman, Karin Ashkenazi, Hila Benjamin, Yael Spector, Eran Goren; eAbstract #22173 2013 ASCO Annual Meeting Chicago

A novel microRNA-based Assay demonstrates 92% accuracy in classification of metastatic tumors from patients diagnosed with carcinoma of unknown primary Mats Sanden, George Pentheroudakis, Nicholas Pavlidis, Brianna St. Cyr, Anna Goussia, Yael Spector, Aikaterini Stoyianni, Alexander Faerman, George Fountzilas, Hila Benjamin, Vassiliki Malamou-Mitsi, Karin Ashkenazi, Robert Wassman Poster presentation AACR, April 2013, Washington DC

Development and validation of a microRNA-based diagnostic assay for classification of renal cell tumors. Mats Sanden, Robert Wassman, Eddie Fridman, Iris Barshack, Yajue Huang, Sofia Zilber, Hila Benjamin, Noga Yerushalmi, Brianna St. Cyr, Yael Spector Poster presentation AACR, April 2013, Washington DC

Further Validation of a MicroRNA-Based Diagnostic Assay for Malignant Mesothelioma M Sanden, M Ben-David, K Ashkenazi, S Tabak, E Klinke, O Zion, M Ezagouri, H Pass and R Aharonov Poster presentation IAP, September 2012, Cape Town, South Africa

A New MicroRNA-based Diagnostic Test for Classification of Kidney Tumors Mats Sanden Proofed Paper Presentation, USCAP, March 2012 Vancouver, Canada

New MicroRNA-Based Diagnostic Test for Lung Cancer Classification Mats Olof Sanden, Hadas Gibori, Michal Kushnir, Gila Lithwick-Yanai, Hila Benjamin, Marluce Bibbo, Craig Thurm, Laurie Horowitz, Yajue Huang, Meora Feinmesser, Iris Barshack, J Steve Hou, Tina B Edmonston, Shlomit Gilad, Sima Benjamin, and Ayelet Chajut. Poster presentation USCAP, March 2012 Vancouver, Canada

A Novel microRNA-Based Test Demonstrate above 90% Accuracy in Classification of Metastatic Tumors from Patients Diagnosed with Carcinoma of Unknown Primary Mats Sanden, George Pentheroudakis, Brianna St. Cyr, Anna Goussia, Danit Lebanony, Katerina Stoyianni, Alexander Faerman, George Fountzilas, Lahav Cohen, Vassiliki Malamou-Mitsi, and Nicholas Pavlidis. Poster presentation USCAP, March 2012 Vancouver, Canada

The composition of inflammatory cells infiltrating rejecting heart allografts in rats is not reflected in the blood or lymph. Sanden M, Rockert LL, Hedman L. Transplant Proc. 1989 Feb; 21(1 Pt. 1):46

Contact this candidate